This site contains promotional information intended only for healthcare professionals resident in Great Britain
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Menu
Close
The content of this website has been produced in line with the ABRYSVO®▼(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain only. ABRYSVO▼ Prescribing Information for Great Britain click here. ABRYSVO▼ Prescribing Information for Northern Ireland click here.
ABRYSVOis a vaccine indicated for the active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV).1
The use of this vaccine should be in accordance with official recommendations.1
RSV can have serious consequences for older adults.2
Many lower respiratory tract infection (LRTI)-related GP visits, hospitalisations, and deaths are attributable to RSV in older adults.3
In the UK it is estimated that, per year, RSV leads to:3
175,000
GP visits
Example
14,000
hospital admissions
Almost
8,000 deaths
Understand more about the dosing, administration and storage of ABRYSVO for older adults.
Learn more about the safety information of ABRYSVO in older adults.
Explore the ABRYSVO resources section for useful videos and materials.
Centres for Disease Control and Prevention (CDC). RSV in Older Adults and Adults with Chronic Medical Conditions. Available at: https://www.cdc.gov/rsv/high-risk/older-adults.html. Accessed January 2024.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024